Daniel O’Connell has over 20 years of venture creation, venture investment and start-up operations experience with a focus on Neurosciences companies. He has served as President and Chief Executive Officer of Acumen Pharmaceuticals, Inc. since December 2014. Under his leadership, Acumen has successfully transitioned from a privately-held, pre-clinical biotech company to a publicly-traded clinical-stage company developing a potential best-in-class treatment for early Alzheimer’s disease.

Mr. O’Connell previously co-founded and served as President and Chief Executive Officer of Functional Neuromodulation Ltd., a clinical-stage company developing deep brain stimulation therapies for Alzheimer’s disease. Mr. O’Connell is a founding member and former managing partner of NeuroVentures Capital, LLC, a firm he helped to invest in emerging neurosciences companies. He earned a B.A. from Brown University and M.B.A. from the University of Virginia.